Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03222375 · ClinicalTrials.gov registry record

SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

A clinical trial of Autism Spectrum Disorder and Autistic Disorder, sponsored by American Federation of Medical Synergetics.

Recruiting
Registry status
80
Enrollment target
2
Study locations

NCT03222375: Recruiting study of Autism Spectrum Disorder and Autistic Disorder, sponsored by American Federation of Medical Synergetics.

NCT03222375 is a study of Autism Spectrum Disorder and Autistic Disorder that is actively recruiting participants, run by American Federation of Medical Synergetics. The registered enrollment target is 80 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03222375, a study of Autism Spectrum Disorder and Autistic Disorder, is actively recruiting participants, sponsored by American Federation of Medical Synergetics.

RECRUITING
Registry status
80 participants
Enrollment target
2
Study locations

Study Summary

Locomotor, transport and information functions in human body systems are carried out by active media in autowave regimes! Any living organism is a (micro-macro-mega) hierarchy of autowave subsystems-an ensemble of loosely coupled subsystems of a simpler structure. From the highest levels of the hierarchy, Autowave Codes-Signals arrive, which determine the transitions of subsystems from one autowave regime to another Autowave interaction (of Complex Coherent Action). Autowave interaction is a process associated with the evolution and interaction of spatial and wave structures in the active media of the organism. Chaos in organism functioning tells about health. Periodicity - Autowave reverberator may presage a disease - Autism Spectrum Disorder; Chaotic nature of oscillations in active media of physiological systems is more optimal for their vital functions than periodic one. Firstly, systems that function in chaotic regimes, can re-arrange themselves faster and easier in case of change of environmental conditions, i.e. the so called adaptive control is more easily implemented in them. Secondly, "spreading" of oscillations strength along comparatively wide frequency band takes place in chaotic regime. When an organism is young and healthy, physiological systems show the elements of chaotic behavior, i.e. irregularity and chaotic dynamics are the extremely important characteristics of health. Decrease in changeability and appearance of stable periodicity of Autowave reverberator are often connected with Autism. The main purpose is to study brain plasticity (the changes that occur in the brain through Autowave reverberator) in children with autism. Research suggests that during development, the brains of children may change in response to their Autowave reverberator differently than the brains of typically developing individuals. Investigators want to understand why and how this difference may contribute to the symptoms of autism spectrum disorder (ASD). In this stu

Primary Outcome

This will be administered by Presence of Clinical protocol CRF-SQUED™and creation Active medium SQUED™ for a patient.

Conditions Studied

Autism Spectrum Disorder Autistic Disorder Neurodevelopmental Disorders Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Child Development Disorders, Pervasive Asperger's Syndrome

Interventions

  • DEVICE SQUED™ series 28.1 home-use

Study Locations (2)

Kentucky

  • World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS - Louisville

Solonka Village, Urozayna Street 41

  • Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics - Lviv

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2017-09-26
Est. Completion 2027-12
American Federation of Medical Synergetics

1 total trials

What NCT03222375 shows while recruiting

NCT03222375 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (41% lower).

The record links to 8 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which SQUED™ series 28.1 home-use is the first listed.

NCT03222375 reports a single indexed study location in Kentucky, Solonka Village, Urozayna Street 41.

Frequently Asked Questions

What is clinical trial NCT03222375 about?

NCT03222375 is a clinical study titled "SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism". Locomotor, transport and information functions in human body systems are carried out by active media in autowave regimes! Any living organism is a (micro-macro-mega) hierarchy of autowave subsystems-an ensemble of loosely coupled subsystems of a simpler structure. From the highest levels of the hier...

What is the current status of trial NCT03222375?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2017-09-26. Estimated completion is 2027-12.

What conditions does trial NCT03222375 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorders, Mental Disorders, Nervous System Diseases.

What interventions are being tested in trial NCT03222375?

The interventions under investigation include: SQUED™ series 28.1 home-use (DEVICE).

Who is sponsoring clinical trial NCT03222375?

This trial is sponsored by American Federation of Medical Synergetics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03222375 being conducted?

This trial has 2 study locations across Kentucky, Solonka Village, Urozayna Street 41. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03222375's enrollment target sits among peer trials

80 89th of 224 higher than 126 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03222375

Source: ClinicalTrials.gov NCT03222375, the US trial registry maintained by the National Library of Medicine. NCT03222375 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.